In addition, limited available data suggest that alpha- and beta-emitting PSMA-targeting derivatives are highly promising for the treatment of prostate cancer, and rapid development of these agents is anticipated in the years ahead assuming adequate isotope availability and appropriate clinical trials [5]. Here, FOLH1 is linked to prostate cancer.